Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort

Journal of Neuro-Oncology

Volumn 131, Issue 1, 2017, Pages 117-124

  Morris, Katrina A ^a,c   Golding, John F ^d   Blesing, Claire ^b   Evans, D Gareth ^e   Ferner, Rosalie E ^f   Foweraker, Karen ^g   Halliday, Dorothy ^a   Jena, Raj ^h   McBain, Catherine ⁱ   McCabe, Martin G ^e   Swampillai, Angela ^f   Warner, Nicola ^b   Wilson, Shaun ^b   Parry, Allyson ^a   Afridi, Shazia K ^f  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF WESTMINSTER   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Bevacizumab; Cardiac failure; Hypertension; Neurofibromatosis type 2; Proteinuria; Toxicity

Indexed keywords

AMLODIPINE; BEVACIZUMAB; CREATININE; CYCLOPHOSPHAMIDE; RAMIPRIL; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ARTHRALGIA; ARTICLE; CONSTIPATION; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART FAILURE; HEART MUSCLE PERFUSION; HEART PALPITATION; HEMATURIA; HEPATOBILIARY DISEASE; HUMAN; HYPERKALEMIA; HYPERTENSION; INFECTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MENORRHAGIA; MENSTRUAL IRREGULARITY; MUCOSA INFLAMMATION; NAUSEA; NEUROFIBROMATOSIS TYPE 2; PAIN; PERIODONTAL DISEASE; PROTEINURIA; PSYCHOSIS; RASH; RECTUM HEMORRHAGE; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR GROWTH; ULCER; URINARY TRACT INFECTION; VOMITING; WOUND HEALING IMPAIRMENT; ADOLESCENT; AGED; CHEMICALLY INDUCED; CHILD; COHORT ANALYSIS; COMPLICATION; MIDDLE AGED; NEURILEMOMA; REGRESSION ANALYSIS; UNITED KINGDOM; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BEVACIZUMAB; CHILD; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NEURILEMMOMA; NEUROFIBROMATOSIS 2; REGRESSION ANALYSIS; UNITED KINGDOM; YOUNG ADULT;

EID: 84992751028     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2276-9     Document Type: Article

References (23)

1. Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-Oncol 12(1):14–18. doi:10.1093/neuonc/nop010
2. Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361(4):358–367. doi:10.1056/NEJMoa0902579
3. Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG, 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neuro 33 (6):1046–1052. doi:10.1097/MAO.0b013e31825e73f5
4. Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF (2014) The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol. doi:10.1007/s00405-014-3398-3
5. Hochart A, Gaillard V, Baroncini M, Andre N, Vannier JP, Vinchon M, Dubrulle F, Lejeune JP, Vincent C, Neve V, Sudour Bonnange H, Bonne NX, Leblond P (2015) Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2. J Neurooncol 124(2):229–236. doi:10.1007/s11060-015-1828-8
6. Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM, Evans DG, McCabe MG, Parry A (2016) Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. Neuro-Oncol Pract. doi:10.1093/nop/npv065 (In press:npv065)
7. Farschtschi S, Kollmann P, Dalchow C, Stein A, Mautner VF (2015) Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2. Eur Arch Oto-Rhino-Laryngol 272 (12):3857–3860. doi:10.1007/s00405-015-3604-y
8. Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR (2016) Efficacy and biomarker study of bevacizumab for hearing loss resulting from Neurofibromatosis Type 2-associated vestibular schwannomas. J Clin Oncol 34(14):1669–1675. doi:10.1200/JCO.2015.64.3817
9. Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT, English Specialist NFRG, Friedman JM, Evans DG (2015) Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. J Med Genet 52(10):699–705. doi:10.1136/jmedgenet-2015-103290
10. Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, Hagel C, Mautner VF (2015) Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. doi:10.1111/ane.12490
11. Essayed WI, Bernard A, Kalamarides M (2015) Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab. J Neurooncol 125(2):445–446. doi:10.1007/s11060-015-1925-8
12. Morris KA, Afridi S, Evans DG, Hensiek A, McCabe MG, Kellett M, Halliday D, Pretorius PM, Parry A (in press) The response of spinal cord Ependymomas to Bevacizumab in patients with Neurofibromatosis type 2. JNS (Spine)
13. Alanin MC, Klausen C, Caye-Thomasen P, Thomsen C, Fugleholm K, Poulsgaard L, Lassen U, Mau-Sorensen M, Hofland KF (2015) Effect of bevacizumab on intracranial meningiomas in patients with neurofibromatosis type 2-a retrospective case series. Int J Neurosci 1–5. doi:10.3109/00207454.2015.1092443
14. Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG 2nd, Stemmer-Rachamimov A, Plotkin SR (2013) Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PloS One 8(3):e59941. doi:10.1371/journal.pone.0059941
15. Izzedine H, Rixe O, Billemont B, Baumelou A, Deray G (2007) Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 50(2):203–218. doi:10.1053/j.ajkd.2007.04.025
16. Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR (2014) Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 73(6):1197–1204. doi:10.1007/s00280-014-2456-2
17. Hornigold RE, Golding JF, Ferner RE, Ferner RE (2011) Neurofibromatosis 2: a novel risk factor for hypertension? Am J Med Gen Part A 155A(7):1721–1722. doi:10.1002/ajmg.a.34035
18. Services USDOHAH, Health NIo, Institute NC (2010) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Accessed 12 January 2015 2015
19. (Nice), NIfHaCE (2011) Hypertension in adults: diagnosis and management Clinical Guideline cg127.
20. Abbas A, Mirza MM, Ganti AK, Tendulkar K (2015) Renal toxicities of targeted therapies. Target Oncol 10(4):487–499. doi:10.1007/s11523-015-0368-7
21. Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 49(2):186–193. doi:10.1053/j.ajkd.2006.11.039
22. Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N (2015) Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 7:133–143. doi:10.2147/CMAR.S77400
23. Groarke JD, Choueiri TK, Slosky D, Cheng S, Moslehi J (2014) Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway. Curr Treat Options Cardiovasc Med 16(9):335. doi:10.1007/s11936-014-0335-0